These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35404191)

  • 21. Age-appropriate solid oral formulations for pediatric applications with a focus on multiparticulates and minitablets: Summary of September 2019 EuPFI workshop.
    Harris D; Hermans E; Klein S; Wagner-Hattler L; Walsh J
    Eur J Pharm Biopharm; 2020 Aug; 153():222-225. PubMed ID: 32580052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA.
    Bajcetic M; Kearns GL; Jovanovic I; Brajovic M; van den Anker JN
    Curr Pharm Des; 2015; 21(39):5668-73. PubMed ID: 26323413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
    Giacoia GP; Taylor-Zapata P; Mattison D
    Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-Appropriate Pediatric Dosage Forms in Japan: Insights into End-User Perceptions From an Observational Cross-Sectional Survey Assessing the Acceptability of Oral Formulation.
    Saito J; Akabane M; Komura M; Nakamura H; Ishikawa Y
    Ther Innov Regul Sci; 2019 Jul; 53(4):455-471. PubMed ID: 30157669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.
    Fabiano V; Mameli C; Zuccotti GV
    Expert Opin Drug Saf; 2012 Jan; 11(1):95-105. PubMed ID: 21548838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patent landscape of pediatric-friendly oral dosage forms and administration devices.
    Karavasili C; Gkaragkounis A; Fatouros DG
    Expert Opin Ther Pat; 2021 Jul; 31(7):663-686. PubMed ID: 33605825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acceptability of different oral dosage forms in paediatric patients in hospital setting.
    Pokharkar V; Sajith M; Vallet T; Akshantal S; Shah R; Ruiz F; Salunke S
    Arch Dis Child; 2022 Sep; 107(9):796-801. PubMed ID: 34799375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conference report: formulating better medicines for children: 4th European Paediatric Formulation Initiative conference.
    Walsh J; Mills S
    Ther Deliv; 2013 Jan; 4(1):21-5. PubMed ID: 23323778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review.
    van Riet-Nales DA; Schobben AF; Egberts TC; Rademaker CM
    Clin Ther; 2010 May; 32(5):924-38. PubMed ID: 20685501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population.
    Venables R; Batchelor H; Hodson J; Stirling H; Marriott J
    Int J Pharm; 2015 Mar; 480(1-2):55-62. PubMed ID: 25601436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Confectionery-based dose forms.
    Tangso KJ; Ho QP; Boyd BJ
    Curr Drug Deliv; 2015; 12(1):56-62. PubMed ID: 25146440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress and limitations of oral peptide delivery as a potentially transformative therapy.
    Tran H; ElSayed MEH
    Expert Opin Drug Deliv; 2022 Feb; 19(2):163-178. PubMed ID: 35255753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extemporaneous drug formulations.
    Nahata MC; Allen LV
    Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. European Paediatric Formulation Initiative workshop report: Improving the administration of oral liquid medicines in paediatrics using dosing syringes and enteral accessories.
    Walsh J; van Riet-Nales D; Hermans E; de Vries R; Hilton G; Blowers P; Salunke S
    Eur J Pharm Biopharm; 2020 Jun; 151():91-97. PubMed ID: 32289491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
    Banerjee S; Pillai J
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
    [No Abstract]   [Full Text] [Related]  

  • 36. Acceptability of orodispersible films for delivery of medicines to infants and preschool children.
    Orlu M; Ranmal SR; Sheng Y; Tuleu C; Seddon P
    Drug Deliv; 2017 Nov; 24(1):1243-1248. PubMed ID: 28856931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges Associated with Route of Administration in Neonatal Drug Delivery.
    Linakis MW; Roberts JK; Lala AC; Spigarelli MG; Medlicott NJ; Reith DM; Ward RM; Sherwin CM
    Clin Pharmacokinet; 2016 Feb; 55(2):185-96. PubMed ID: 26245673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral delivery of peptide therapeutics in infants: Challenges and opportunities.
    Gleeson JP; Fein KC; Whitehead KA
    Adv Drug Deliv Rev; 2021 Jun; 173():112-124. PubMed ID: 33774115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.
    van Riet-Nales DA; Schobben AF; Vromans H; Egberts TC; Rademaker CM
    Arch Dis Child; 2016 Jul; 101(7):662-9. PubMed ID: 26979250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical Reviews on Pediatric Dosage Form Developments and Medical Devices.
    Kaur G; Nagpal D; Nagpal K
    Crit Rev Ther Drug Carrier Syst; 2020; 37(6):553-590. PubMed ID: 33426833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.